Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
C9JPN9
UPID:
UL17C_HUMAN
Alternative names:
-
Alternative UPACC:
C9JPN9
Background:
Ubiquitin carboxyl-terminal hydrolase 17-like protein 12 plays a pivotal role in cellular processes by acting as a deubiquitinating enzyme. It specifically removes conjugated ubiquitin from proteins, influencing cell proliferation, cell cycle progression, apoptosis, cell migration, and response to viral infections.
Therapeutic significance:
Understanding the role of Ubiquitin carboxyl-terminal hydrolase 17-like protein 12 could open doors to potential therapeutic strategies.